TK-004

N/A

Report date: 2026/04/08 20:02:35

Base Information

Drug NameTK-004

Drug Alias NameTK-004

ClassificationVaccines > Development/production technology > Nucleic acid vaccine > DNA vaccineVaccines > Application > Prophylactic vaccineCell and gene therapy > Gene therapy > Plasmid

Mechanisms of ActionSARS-CoV-2 Spike glycoprotein receptor binding domain antagonists

TargetsSARS-CoV-2 Spike glycoprotein receptor binding domain

Therapy Area/IndicationsCoronavirus Disease 2019 (COVID-19)

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryItaly

CombinationsNo

Global Highest StatusPhase 1 Clinical

Highest Status in ChinaN/A

Originator CompaniesTakis

China Registration ClassN/A

Develop Information

Active CompaniesTakis

Inactive CompaniesN/A

Active IndicationsCoronavirus Disease 2019 (COVID-19)

Inactive IndicationsN/A

Other Information

ATC CodeN/A